Unique Features

  • Assessment of Bone Resorption in Rodents 1, 2, 3
  • Ovariectomised (OVX) rats and mice
  • Thyroidparathyroidectomised (TPTX) rats
  • Rat and mouse models of bone metastases
  • Knock-out and transgenic mice with effect in bone resorption
  • Assessment of Bone Resorption in Tissue Culture
  • Calvariae, tibiae, or metatarsals from rats and mice
  • Multi-disciplinary use -measuring urine and serum samples
  • All reagents ready for use
  • A complete assay panel supporting bone research

RatLaps (CTX-I) EIA is an enzyme-linked immunosorbent assay for the quantitative determination of bone-related degradation products from C-terminal telopeptides of type I collagen in rat/mouse serum or urine, and from rat/mouse bone released into cell culture supernatants by osteoclasts. The assay is for research use only.

Type I collagen accounts for more than 90% of the organic matrix of bone and is synthesised primary in bone.

During renewal of the skeleton bone matrix is degraded and consequently fragments of type I collagen are released into circulation. The RatLaps (CTX-I) EIA is based on the observation that certain C-telopeptide degradation products from type I collagen released during osteoclastic bone resorption.

The RatLaps (CTX-I) EIA is based upon the competitive binding of a polyclonal antibody to soluble RatLaps antigens EKSQDGGR or to immobilised RatLaps antigens. Briefly, the polyclonal antibody is raised against a synthetic peptide having a sequence (EKSQDGGR) specific for a part of the C-terminal telopeptide α1 chain of rat type I collagen.

For standardisation of the RatLaps (CTX-I) EIA a synthetic peptide (EKSQDGGR) that is specific for the C-terminal telopeptide α1 chain of type I collagen in rats has been used.

Mackenzie NC et al., Altered bone development and an increase in FGF-23 expression in Enpp1(-/-) mice. PLoS One. 2012;7(2):e32177

Pennisi P et al., L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats. J Endocrinol Invest. 2009 Jun;32(6):546-51.

Schaller S et al., In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol. 2005 Oct;3(5):553-80.